Riskpilot← Back to searchSign inGet full accessAddLife Development AB
ABActiveOrg 5564908373Birger Jarlsgatan 43Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19943 employees
Revenue 2024
SEK 98,3M
+10% vs 2023
EBITDA margin
-2.7%
-61% vs 2023
Equity ratio
26.1%
Financial strength
Net profit 2024
SEK -326,7M
+25% vs 2023
| Revenue | SEK 98,3M | +10% |
| EBITDA | SEK -2,6M | -61% |
| Net profit | SEK -326,7M | +25% |
| Total assets | SEK 7,7B | -3% |
| Equity | SEK 2B | -4% |
| Employees | 3 | — |
Legal name
AddLife Development AB
Org number
5564908373
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15 augusti 1994
Share capital
SEK 100 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Föremål för bolagets verksamhet är att marknadsföra, sälja och distribuera laboratorieprodukter avsedda för in vitro-metoder nationellt och internationellt, att tillhandahålla tjänster inom detta område samt inneha och förvalta företag, ävensom driva annnan därmed förenlig verksamhet.
Address
Birger Jarlsgatan 43
Email
info@add.life
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 41 650 | 45 018 | 38 937 | 49 924 | 66 436 | 87 675 | 89 240 | 98 272 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | −1 123 | 1 915 | −1 725 | −3 716 | −4 594 | 3 017 | 618 | −1 629 | −2 618 |
| Depreciation & amort. | −2 052 | −2 759 | −2 759 | −2 620 | −2 237 | −2 229 | −1 622 | −61 | −0 |
| EBIT | −3 175 | −844 | −4 484 | −6 336 | −6 831 | 788 | −1 004 | −1 690 | −2 618 |
| Net financials | 49 622 | 80 692 | 128 274 | 129 923 | 132 664 | 206 546 | −102 323 | −413 292 | −393 590 |
| Profit before tax | 53 517 | 89 448 | 142 460 | 148 576 | 158 247 | 359 536 | 114 257 | −434 334 | −326 694 |
| Tax | −183 | −15 | −17 | −2 236 | −3 120 | −11 731 | −184 | −2 050 | −43 |
| Net profit | 53 334 | 89 433 | 142 443 | 146 340 | 155 127 | 347 805 | 114 073 | −436 384 | −326 737 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 077 215 | 1 403 160 | 1 443 564 | 1 798 506 | 2 651 380 | 7 923 383 | 8 592 467 | 7 876 991 | 7 655 423 |
| Equity | 291 017 | 380 450 | 522 893 | 669 233 | 824 360 | 1 172 166 | 1 286 239 | 2 080 012 | 1 998 361 |
| Long-term debt | 521 242 | 992 987 | 912 300 | 1 114 180 | 1 730 781 | 6 646 680 | 7 237 777 | 5 704 648 | 5 560 240 |
| Short-term debt | 264 956 | 29 723 | 8 371 | 15 092 | 96 239 | 86 037 | 49 951 | 92 331 | 96 822 |
| Total debt | 786 198 | 1 022 710 | 920 671 | 1 129 272 | 1 827 020 | 6 732 717 | 7 287 728 | 5 796 979 | 5 657 062 |
EBITDA margin
-2.7%
This company
15.8%
Market median
-117% vs market
20162024
Equity ratio
26.1%
This company
38.2%
Market median
-32% vs market
20162024
Return on equity
-16.4%
This company
18.4%
Market median
-189% vs market
20162024
Net profit margin
-332.5%
This company
8.1%
Market median
-4205% vs market
20162024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20162024
Debt / equity
2.83×
This company
0.62×
Market median
-356% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-04-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AC Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
HE Chief Auditor | Chief Auditor | 2023 | — | — |
PJ Chief Auditor | Chief Auditor | 2022 | — | — |
FO Chief Auditor | Chief Auditor | 2026 | — | — |
MA Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
AddLife AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AddLife AB
AddLife Development AB (this company)Mediplast Holding ApsMediplast Iberia SlMediplast A/SImmuno Diagnostics OyRopox A/SMaia Holding B.V. - Bioconnect GroupMediplast Benelux B.V.Primacy Healthcare 21 LimitedTriolab OyMediplast GmbhTriolab ASVäino Korpinen OyyBionordika (Denmark) A/SRemi GmbhDach Medical Group Holding AgBio-Connect B.V.Fischer Medical ApsBionordika Bergman ASLab-Vent Controls A/SVision Ophthalmology Holding One GroupMediplast S.R.L.Mba Italia, S.R.lEdge Medical Ltd.Mba Incoporado S.L.Mediplast ASMediplast Sataside OyFenno Medical OyMediplast AustralienBergman Diagnostika ASFunksjonsutstyr ASBiocat GmbhHepro ASBiomedica Italia S.R.L.Triolab A/SHospidana A/SHolm & Halby A/SMba Incorporade S.L.Bionordika (Finland) OyEuroclone S.P.A.Triolab Baltic OüTechnipro Pulmomed Pty LtdBiomedica Medizinprodukte GmbhBonsailab S.L.U.HOSPIDANA A/SMEDIPLAST A/SHOLM & HALBY A/SBIONORDIKA (DENMARK) A/SEDGE MEDICAL LTD.VÄINO KORPINEN OYYFUNKSJONSUTSTYR ASIMMUNO DIAGNOSTICS OYMEDIPLAST S.R.L.BIO-CONNECT B.V.DACH MEDICAL GROUP HOLDING AGTRIOLAB ASFENNO MEDICAL OYVISION OPHTHALMOLOGY HOLDING ONE GROUPTRIOLAB BALTIC OÜLAB-VENT CONTROLS A/SMEDIPLAST AUSTRALIENTECHNIPRO PULMOMED PTY LTDBIOMEDICA ITALIA S.R.L.Biolin Scientific LtdBiolin Scientific OyBiolin (Shanghai) Trading Co., LtdBIOLIN SCIENTIFIC OYBIOLIN SCIENTIFIC LTDBIOLIN (SHANGHAI) TRADING CO., LTDBONSAILAB S.L.U.MEDIPLAST ASFISCHER MEDICAL APSREMI GMBHMAIA HOLDING B.V. - BIOCONNECT GROUPROPOX A/SBERGMAN DIAGNOSTIKA ASMEDIPLAST IBERIA SLEUROCLONE S.P.A.TRIOLAB OYMEDIPLAST BENELUX B.V.MEDIPLAST GMBHPRIMACY HEALTHCARE 21 LIMITEDHEPRO ASTRIOLAB A/SMBA INCORPORADE S.L.BIONORDIKA (FINLAND) OYBIOMEDICA MEDIZINPRODUKTE GMBHMBA INCOPORADO S.L.MBA ITALIA, S.R.LBoard members of AddLife Development AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Christina Rubenhag | Chief Executive Officer | 0 companies |
| Helena Eva Marie Nilsson | Chief Auditor | 0 companies |
| Per Jonas Eriksson | Chief Auditor | 0 companies |
| Fredrik Olof Ingvar Göransson | Chief Auditor | 0 companies |
| Martin Almgren | Chief Executive Officer | 0 companies |
| Eva Kristina Willgård | Chairman | 0 companies |
| Peter Mikael Simonsbacka | Board of Directors | 0 companies |
| Fredrik Olof Dalborg | Chairman | 0 companies |